Sino Biological, Inc. has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), designed to enhance artificial intelligence-driven high-throughput screening for antibody drug discovery. The kit leverages cell-free protein synthesis technology to produce target proteins and antibodies rapidly in vitro, bypassing the limitations of traditional cell-based expression systems. This integration with AI-powered platforms aims to accelerate the identification and optimization of antibody candidates, reducing development timelines and costs.
Based on an E. coli lysate fully supplemented with transcription and translation components, XPressMAX™ enables direct protein synthesis from plasmid or PCR templates. Specifically tailored for antibody drug discovery, it supports rapid expression and validation of VHH, scFv, Fab, and miniproteins. Sino Biological has utilized this kit to establish a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching the rapid iteration of AI systems.
Key highlights of the kit include ultra-fast synthesis completed in just 3 hours, a success rate greater than 99%, and support for complex disulfide bonding to ensure native folding and bioactivity without additional enhancers. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., stated, "Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality." Dr. Jie Zhang, Sino Biological’s General Manager, added, "AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours."
The launch addresses the growing need for faster protein production in the face of AI-accelerated drug discovery. By enabling rapid synthesis of complex proteins, the kit facilitates iterative screening and optimization, potentially reducing the time from target identification to lead candidate selection. This could have significant implications for the development of therapeutics for diseases with urgent unmet needs.
Researchers can explore more about XPressMAX™ by visiting Sino Biological's product page or request a free sample via this link. Additional information about Sino Biological's cell-free expression solutions is available here.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. The company serves researchers in over 90 countries and maintains a stringent quality management system across all products. The XPressMAX™ kit represents a step forward in empowering AI-driven drug discovery with efficient, high-throughput protein synthesis capabilities.
